/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT
INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR
DISSEMINATION IN THE UNITED STATES/
MONTREAL, Sept. 5 /CNW Telbec/ - Ranaz Corporation (TSXV: RNZ), ("Ranaz"
or the "Corporation") a company specializing in the manufacture and marketing
of protein and dietary supplements related to weight loss and obesity
treatments, announced today that it had filed a preliminary short form
prospectus with the securities regulatory authorities of British Columbia,
Alberta, Ontario and Québec with respect to a best efforts offering (the
"Offering") of units of the Corporation.
Each unit will consist of one common share of the Corporation and one
half of a common share purchase warrant. Each full common share purchase
warrant entitles the holder thereof to purchase one additional common share of
the share capital of the Corporation.
The Offering will be led by Loewen, Ondaatje, McCutcheon Limited with a
syndicate comprised of Blackmont Capital inc. (collectively, the "Agents").
Final pricing and determination of the number of common shares to be sold
pursuant to the Offering will occur immediately prior to the filing of the
(final) short form prospectus in respect of the Offering.
The transaction is subject to the receipt of all necessary regulatory and
stock exchange approvals.
The securities being offered have not been and will not be registered
under the U.S. Securities Act of 1933 or any State securities legislation of
the United States. They may not be offered, sold or delivered in the United
States except as part of transactions that are exempt from the registration
requirements of the U.S. Securities Act. The term "United States" has the
meaning ascribed to it in Regulation S promulgated under the U.S. Securities
Act. This release does not constitute an offer for sale of securities in the
About Ranaz Corporation
Ranaz is a corporation specializing in the manufacture and marketing of
protein and dietary supplements in relation to weight loss and obesity
treatments. Its mission is to design, develop and market nutritional, protein
and dietary supplements under its own corporate brands, such as Protidiet and
ProtiLife, as well as under private labels. Ranaz shares have traded under the
symbol RNZ on the TSX Venture Exchange since December 29, 2006.
Certain statements contained in this news release, other than statements
of fact that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown, many of which are beyond Ranaz's control.
Such risks include but are not limited to: the impact of general economic
conditions, changes in the regulatory environment in the jurisdictions in
which Ranaz does business, stock markets volatility, fluctuations in costs,
and changes to the competitive environment due to consolidation, as well as
other risks disclosed in public filings of Ranaz. Consequently, actual future
results may differ materially from the anticipated results expressed in the
forward-looking statements. The reader should not place undue reliance, if
any, on the forward-looking statements included in this news release. These
statements speak only as of the date made and Ranaz is under no obligation and
disavows any intention to update or revise such statements as a result of any
event, circumstances or otherwise.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.
For further information:
For further information: Martin Vidal, Executive Vice President, Ranaz
Corporation, (450) 491-7106, Ext. 213, email@example.com; Jean
Walter, Vice President, MaisonBrison, (514) 731-0000, Ext. 223,